Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic BM-MSC intradiscal therapy versus sham for chronic low back pain due to lumbar degenerative disc disease
2017-002092-25Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- May 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic bone marrow-derived mesenchymal stromal cells in lumbosacral disc disease (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoints: Clinical response at month 12 and Pain and disability efficacy over follow-up. Started May 2018; status: active.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
lumbosacral disc disease
Beyond the preview
Go deeper on 2017-002092-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002092-25.